Atlas Trials

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Clinical trial NCT05697003 · UNKNOWN

Trial details

NCT number
NCT05697003
Sponsor
Respirent Pharmaceuticals Co Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Bioequivalence
Start date
2023-02-17
Primary completion
2023-03-31
Enrollment
34

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.